Treatment-Resistant Depression Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Treatment-Resistant Depression Market Analysis
The Treatment- Resistant Depression market is projected to register a CAGR of 4% during the forecast period.
During COVID-19, the mental state of the individuals was greatly affected, and consequently, most of the persons were suffering from different psychiatric and neuropsychiatric disorders. As per the study published in October 2020, titled 'The Impact of the COVID-19 Pandemic on the Health and Coping Behaviors of Patients With Treatment-Resistant Depression' the COVID-19 pandemic has affected the health of patients with TRD in both positive and negative ways. As the goal of government preventive strategies is to protect and promote public health, regular attention should be paid to the negative effects of long-term exposure to pandemic-related news on this vulnerable population. Therefore, COVID-19 has provided the opportunity for market players for innovative and effective treatment procedures to address the global burden of such increasing anxiety disorders, thereby it is expected to impact the market positively.
The market is majorly driven by rising cases of depression, increasing awareness about depression, and the emergence of novel drugs. According to the World Health Organization (WHO), data updated in June 2021, more than 700,000 people suicide every year, and it is the fourth leading cause of death among 15-19-year-olds. Similarly, In countries such as the United Kingdom in the United States, which are characterized by their fast-paced economies, the percentage of the affected population of every age is quite high. According to the Anxiety and Depression Foundation facts and statistics updated in June 2022, generalized anxiety disorder will affect 6.8 million adults or 3.1% of the United States population per year. Thus, the rising cases of depression across the world are expected to drive the overall growth of the market studied over the forecast period.
Moreover, the manufacturer's interest in developing new medication the United States Food and Drug Administration (USFDA) approval is triggering the growth of the market. For instance, in July 2022, Abbott received the United States Food and Drug Administration's approval to use its deep brain stimulators (DBS) device for treatment-resistant depression (TRD). Moreover, in March 2019, the FDA approved Spravato-non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for the TRD treatment in adults. It is the first-ever approved NMDA therapy for TRD.
However, severe high costs and a rise in adverse drug reactions significantly hinder the market's growth.
Treatment-Resistant Depression Market Trends
This section covers the major market trends shaping the Treatment-Resistant Depression Market according to our research experts:
The Retail Pharmacies Segment is Expected to Hold a Major Market Share in the Treatment- Resistant Depression Market
The Retail pharmacies segment is expected to hold a major share in the studied market during the forecast period. This is mainly due to the factors such as the increasing prevalence of TRDs, increasing research studies, and product launches. A retail pharmacy is referred to as a pharmacy acting as a retail store, selling drugs to patients. Retail pharmacists are responsible for dispensing medications correctly for customers to use at home, as well as educating the customers on their medications and answering any questions the customers have.
In April 2020, an article titled' Major Depressive disorder' stated that major depressive disorder was ranked as the third cause of the burden of disease worldwide in 2001 by the World Health Organization (WHO), which has projected that this disease will rank first by 2030. It is diagnosed when an individual has a persistently low or depressed mood or decreased interest in pleasurable activities, lack of energy, poor concentration, appetite changes, or suicidal thoughts.
Moreover, as per the study published in August 2021, titled 'Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study' The prevalence of TRD in Latin American sites among patients with MDD was 29% (429 patients). By country, the lowest prevalence of TRD was observed in Mexico (21%) and the highest was observed in Brazil (40%); prevalences in Colombia and Argentina were 32% and 33%, respectively. Overall, the prevalence of TRD was numerically higher in public sites of care (31%) than in private sites of care (27%), and varied by more specific categorizations (19% among patients in public psychiatric clinical sites vs 60% among patients at general hospitals. Thus, the statistics indicate that there is an increase in the prevalence of treatment-resistant depression, which is expected to increase the distribution of drugs through retail pharmacies, thereby contributing to the market growth.
Product launches are another factor in the growth of the market. For instance, in December 2021, Dr. Reddy launched enlafaxine ER Tablets in the United States market. The product is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150mg, and 225mg, of Osmotica Pharmaceutical U.S. LLC. A selective serotonin and norepinephrine reuptake inhibitor (SNRI), Venlafaxine Extended-Release tablets, are indicated for major depressive disorder (MDD) and social anxiety disorder (SAD). The increasing product launches are anticipated to fuel the provision of the drugs through retail pharmacies, thereby boosting the market growth.
Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.
The increasing cases of depression are one of the major factors that are expected to drive the overall growth of the treatment-resistant depression market. Moreover, the rise in the geriatric population in the United States is expected to create more opportunities for the market players in the region.
According to the Anxiety and Depression Association of America, in 2021, anxiety disorder is one of the most common mental illnesses in the United States, affecting approximately 40 million American adults every year, which is 18.1% of the total population United States. Additionally, more than 16.1 million American adults suffer from major depressive disorder every year and it is more prevalent in women than men. Moreover, as per the study published in 2021, titled 'The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States', the estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD. The total annual burden of medication-treated MDD among the United States population was USD 92.7 billion, with USD 43.8 billion (47.2%) attributable to TRD.
Thus, the increasing prevalence of disorders and increasing demand for treatment-resistant depression are expected to drive the growth of the market during the forecast period.
Treatment-Resistant Depression Industry Overview
The Treatment- Resistant Depression market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AstraZeneca, Pfizer, Inc, GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb Company, Forest Laboratories, Johnson and Johnson, Schering Plough Corporation, Vistagen Therapeutics, Inc, Wyeth, and Others
Treatment-Resistant Depression Market Leaders
-
AstraZeneca
-
Pfizer
-
GlaxoS
-
Eli Lilly and Company
-
Johnson and Johnson
*Disclaimer: Major Players sorted in no particular order
Treatment-Resistant Depression Market News
- In July 2022, Abbott received the United States Food and Drug Administration's approval to use its deep brain stimulators (DBS) device for treatment-resistant depression (TRD),
- In December 2021, Dr. Reddy's launched following the United States Food and Drug Administration approval, the product equivalent to Venlafaxine extended release, an anti-depressant tablet.
Treatment-Resistant Depression Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Prevalence of Depression
- 4.2.2 Increase in chronic diseases
-
4.3 Market Restraints
- 4.3.1 High Cost and Rise in Adverse Drug Reaction
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Selective Serotonin reuptake inhibitors
- 5.1.2 Monoamine Oxidase Inhibitors
- 5.1.3 Tricyclic Antidepressant Inhibitors
- 5.1.4 Others
-
5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Online Pharmacies
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AstraZeneca
- 6.1.2 Pfizer, Inc
- 6.1.3 GlaxoSmithKline Plc
- 6.1.4 Eli lilly and Company
- 6.1.5 Bristol-Myers Squibb Company
- 6.1.6 Forest Laboratories
- 6.1.7 Johnson and Johnson
- 6.1.8 Scherinhg Plough Corporation
- 6.1.9 Vistagen therapeutics, Inc
- 6.1.10 Wyeth
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Treatment-Resistant Depression Industry Segmentation
As per the scope of the report, depression that does not respond or show any signs of improvement when treated with an antidepressant is known as treatment-resistance depression. The Treatment- Resistant Depression market is segmented by Drug Class (Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant Inhibitors, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values ( in USD million) for the above segments.
| By Drug Class | Selective Serotonin reuptake inhibitors | |
| Monoamine Oxidase Inhibitors | ||
| Tricyclic Antidepressant Inhibitors | ||
| Others | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Treatment-Resistant Depression Market Research FAQs
What is the current Global Treatment-Resistant Depression Market size?
The Global Treatment-Resistant Depression Market is projected to register a CAGR of 4% during the forecast period (2024-2029)
Who are the key players in Global Treatment-Resistant Depression Market?
AstraZeneca, Pfizer, GlaxoS, Eli Lilly and Company and Johnson and Johnson are the major companies operating in the Global Treatment-Resistant Depression Market.
Which is the fastest growing region in Global Treatment-Resistant Depression Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Treatment-Resistant Depression Market?
In 2024, the North America accounts for the largest market share in Global Treatment-Resistant Depression Market.
What years does this Global Treatment-Resistant Depression Market cover?
The report covers the Global Treatment-Resistant Depression Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Treatment-Resistant Depression Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Treatment-Resistant Depression Industry Report
Statistics for the 2024 Global Treatment-Resistant Depression market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Treatment-Resistant Depression analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
